Back to results
US 2015/0105351 A1Published application
Compounds and methods for treating hiv infections
AssigneeYale University
InventorsWilliam L. Jorgensen, Karen S. Anderson
Life of this patent
Estimating the term…
Abstract
The present invention is directed to novel nanomolar and picomolar inhibitors of HIV reverse transcriptase, pharmaceutical compositions therefrom and methods for inhibiting reverse transcriptase and treating HIV infections, especially included drug resistant strains of HIV-1 and HIV-2 and/or secondary disease states and/or conditions which occur as a consequence of HIV infection.
Claims41
A compound of the formula (I):
- wherein:
- R1 is H, a halogen (F, Cl, Br, I, especially F, Cl, or Br), CN, NO2, an optionally substituted alkyl group, preferably a C1-C6 alkyl group (preferably CH3 and including CF3);
- R3 is H, OH, a C1-C3 alkyl group which is optionally substituted with up to 3 halogens (preferably F), a halogen (preferably F, Cl or Br), NO2 or CN;
- Rp is an optionally substituted five- or six-membered heterocycle, including pyrimidine derivatives preferably linked at the 1-position of the pyrimidine, more often a uracil moiety linked at the 1-position which is optionally substituted at the 5- or 6-position (often the 5-position) with a substituent R2a;
- R2a is H, halogen (preferably F, Cl or Br), optionally substituted C1-C3 alkyl (preferably methyl, ethyl or trifluoromethyl), optionally substituted —O—(C1-C3) alkyl (methyl, ethyl, propyl, isopropyl), including O—CF3, CN;
- W is N or C;
- X1 is
- O or N—RX when W is C, and
- when W is N;
- Z is
- (the double bond can be on either side of the carbon depending on X1 and Y1);
- Y1 is
- O or N—RY when W is C, and
- when W is N;
- R2 is H, a C1-C6 alkyl (preferably C1-C3 alkyl, including cyclopropyl) or a C2-C6 alkenyl optionally substituted with up to three fluorines (e.g. CF3), CN or halogen (F, Br, Cl, I), C1-C6alkoxy;
- C1-C6 hydroxyalkyl, C1-C6 alkoxyalkyl, C1-C6 polyoxyalkyl (e.g., methoxyethoxy) or a vinyl-R2 (substituted on the first or second carbon of the vinyl group, preferably on the second carbon cis or trans, more preferably trans);
- and
- RX and RY are each independently H or a C1-C6 alkyl (or a C1-C3 alkyl) group, optionally substituted with one or two hydroxyl groups;
- m is 0, 1, 2, 3 or 4 and n is 0, 1, 2 or 3;
- and the pharmaceutically acceptable salts, solvates and polymorphs thereof;
- with the proviso that the following compounds are excluded:
- (1) the compound of formula I where Rp is uracil, W is C, X1 is N—RX, RX is H, Y1 is
- where R2 is H, R1 is 4-H, R3 is 6-H, Z is
- where R2 is H and m and n are 1;
- (2) the compound of formula I where Rp is uracil, W is N, X1 is
- where R2 is H, Y1 is
- where R2 is H, R1 is 4-H, R3 is 6-H, m and n are 1, Z is
- and R2 bound to the Z carbon is either CH3 or CN;
- (3) the compound of formula I where Rp is uracil, W is C, X1 is O, Y1 is
- R2 is H, Z is
- m and n are 1, R1 is 4-Cl, R3 is 6-H and R2 bound to the Z carbon is H or CH3;
- and
- (4) the compound of formula I where Rp is uracil, W is C, X1 is
- where R2 is H, Z is
- where R2 is H, Y1 is O, R1 is 4-Cl, R3 is 6-H and m and n are 1.
32 more elements
A compound of the formula (IIA):
- wherein:
- X and X1 are independently H, a halogen (F, Cl, Br, I, especially F, Cl, or Br), CN, NO2, an optionally substituted alkyl group, preferably a C1-C6 alkyl group (preferably CH3 and including CF3);
- Y and Y1 are independently H, a C1-C6 alkyl optionally substituted with up to three fluorines (e.g. CF3), CN or halogen (F, Br, Cl, I), C1-C6 alkoxy;
- C1-C6 hydroxyalkyl, C1-C6 alkoxyalkyl, C1-C6 polyoxyalkyl (e.g., methoxyethoxy);
- Z and Z1 are independently H, OH, a C1-C3 alkyl group which is optionally substituted with up to 3 halogens (preferably F), a halogen (preferably F, Cl or Br), NO2 or CN;
- and the pharmaceutically acceptable salts, solvates and polymorphs thereof.
3 more elements
A compound of the formula (II):
- wherein:
- X is H, a halogen (F, Cl, Br, I, especially F, Cl, or Br), CN, NO2, an optionally substituted alkyl group, preferably a C1-C6 alkyl group (preferably CH3 and including CF3);
- Y is H, a C1-C6 alkyl optionally substituted with up to three fluorines (e.g. CF3), CN or halogen (F, Br, Cl, I), C1-C6 alkoxy;
- C1-C6 hydroxyalkyl, C1-C6 alkoxyalkyl, C1-C6 polyoxyalkyl (e.g., methoxyethoxy);
- Z is H, OH, a C1-C3 alkyl group which is optionally substituted with up to 3 halogens (preferably F), a halogen (preferably F, Cl or Br), NO2 or CN;
- and
- m and p are independently 0, 1, 2, 3 or 4 and n is 0, 1, 2 or 3;
- and the pharmaceutically acceptable salts, solvates and polymorphs thereof.
5 more elements
A compound according to the chemical structure:
- where X is H, —Cl or F;
- Y is H, CH3, Cl, F or CN;
- and
- Z is H, CH3, Cl or F, or
- a pharmaceutically acceptable salt, solvate or polymorph thereof.
2 more elements
Dependencies are inferred from the claim text.